Skip to main content
Acta Bio Medica : Atenei Parmensis logoLink to Acta Bio Medica : Atenei Parmensis
. 2022 Jan 19;92(6):e2021395. doi: 10.23750/abm.v92i6.12030

The Temporal Correlation Between Positive Testing and Death in Italy: From the First Phase to the Later Evolution of the COVID-19 Pandemic

Vincenzo d’Alessandro 1,§, Nicole Balasco 2,§, Pietro Ferrara 3,4,, Luigi Vitagliano 2
PMCID: PMC8823554  PMID: 35075070

Abstract

Background and aim:

After the global spread of the coronavirus disease 2019 (COVID-19), research has concentrated its efforts on several aspects of the epidemiological burden of pandemic. In this frame, the presented study follows a previous analysis of the temporal link between cases and deaths during the first epidemic wave (Phase 1) in Italy (March-June 2020).

Methods:

We here analyze the COVID-19 epidemic in the time span from March 2020 to June 2021.

Results:

The elaboration of the curves of cases and deaths allows identifying the temporal shift between the positive testing and the fatal event, which corresponds to one week from W2 to W33, two weeks from W34 to W41, and three weeks from W42 to W67. Based on this finding, we calculate the Weekly Lethality Rate (WLR). The WLR was grossly overestimated (~13.5%) in Phase 1, while a mean value of 2.6% was observed in most of Phase 2 (starting from October 2020), with a drop to 1.4% in the last investigated weeks.

Conclusions:

Overall, these findings offer an interesting insight into the magnitude and time evolution of the lethality burden attributable to COVID-19 during the entire pandemic period in Italy. In particular, the analysis highlighted the impact of the effectiveness of public health and social measures, of changes in disease management, and of preventive strategies over time. (www.actabiomedica.it)

Keywords: COVID-19, Italy, lethality rate, SARS-CoV-2, weekly lethality rate


Appendix Supplementary files

Introduction

The Coronavirus Disease 2019 (COVID-19) pandemic that started in China in the last months of 2019 is causing a global health emergency, the solution of which seems yet far to be achieved despite the enormous efforts made to mitigate its spread, and the development of therapeutic and effective preventive strategies (1-3). Currently, the official number of cases (i.e., infected subjects) is approaching 200 million with nearly four million deaths (4,5). The pandemic has non-uniformly affected almost all continents and countries (4), often with a fast and intricate evolution resulting from the combination of many factors, namely (a) the use of personal protective equipment, (b) restrictions to the people mobility applied by public authorities that were periodically released in a difficult attempt to prevent or limit the infections without destroying local economies, (c) the seasonality of viral respiratory diseases, (d) the progressive appearance of SARS-CoV-2 variants endowed with increased infection rates, and (e) the recent implementation of vaccination campaigns (2,3,6,7).

In this scenario, the gathering of information on the burden of the disease is of utmost importance for better understanding the origin and evolution of the pandemic spreading, as well as the effectiveness of public health interventions (3). By analyzing the evolution of the pandemic outbreak in Italy, the center of the first main outbreak among Western countries, we have recently examined the temporal correlation between the positive COVID-19 testing and deaths in the first phase, i.e., the period March-June 2020 (8,9). In particular, we found, on average, a one-week delay between the positive test and the fatal event. Despite the straightforwardness of the approach and the heterogeneity of the available data, we exploited this finding to propose a lethality measure denoted as Weekly Lethality Rate (WLR), which is based on the ratio between the number of deaths occurring in a certain week and the number of positive tests detected in the previous weeks (8).

In order to further investigate the lethality impact of the infection in Italy, we have extended this analysis to the entire pandemic, by monitoring the temporal link between positive testing and death from the summer 2020 to June 2021. As for the initial phase, we quantified the temporal correlation between these events, and found a progressively increasing time gap. On this basis, we conceived an approach to generalize the WLR. The implications of these findings on the evolution of the Italian outbreak will be discussed, considering the impact and effectiveness of political interventions, changes in disease management, and preventive strategies.

Materials and Methods

Study Design and Data Source

We performed a longitudinal retrospective analysis on the time-trend of the lethality due to COVID-19 in Italy through the data from the freely accessible national integrated surveillance system (10). More specifically, we gathered the daily number of diagnostic tests, confirmed cases, and deceased related to SARS-CoV-2 (Table S1). We traced data over 67 weeks (denoted as W1, W2, . . ., W67) covering the period from March 2nd, 2020 to June 13th, 2021 (Table S2).

Table S1.

Daily cases, deaths, and tests in the time interval March 2nd, 2020 - June 13th, 2021 collected from the Reports of the Italian National Institute of Health (ISS)

Date Daily cases Daily deaths Daily tests
02-Mar 335 11 2218
03-Mar 466 27 2511
04-Mar 587 28 3981
05-Mar 769 41 2525
06-Mar 778 49 3997
07-Mar 1247 36 5703
08-Mar 1492 133 7875
09-Mar 1797 97 3889
10-Mar 1577 168 6935
11-Mar 1713 196 12393
12-Mar 2651 189 12857
13-Mar 2547 250 11477
14-Mar 3497 175 11682
15-Mar 3590 368 15729
16-Mar 3385 349 13063
17-Mar 3374 345 10695
18-Mar 4207 475 16884
19-Mar 5322 427 17236
20-Mar 5986 627 24109
21-Mar 6557 793 26336
22-Mar 5560 651 25180
23-Mar 4790 601 17066
24-Mar 5249 743 21496
25-Mar 5210 683 27481
26-Mar 6153 712 36615
27-Mar 5909 919 33019
28-Mar 5974 889 35447
29-Mar 5217 756 24504
30-Mar 4050 812 23329
31-Mar 4053 837 29609
01-Apr 4782 727 34455
02-Apr 4668 760 39809
03-Apr 4585 766 38617
04-Apr 4805 681 37375
05-Apr 4316 525 34237
06-Apr 3599 636 30271
07-Apr 3039 604 33713
08-Apr 3836 542 51680
09-Apr 4204 610 46244
10-Apr 3951 570 53495
11-Apr 4694 619 56609
12-Apr 4092 431 46720
13-Apr 3153 566 36717
14-Apr 2972 602 26779
15-Apr 2667 578 43715
16-Apr 3786 525 60999
17-Apr 3493 575 65705
18-Apr 3491 482 61725
19-Apr 3047 433 50708
20-Apr 2256 454 41483
21-Apr 2729 570 52126
22-Apr 3370 401 63101
23-Apr 2646 464 66658
24-Apr 3021 420 62447
25-Apr 2357 415 65387
26-Apr 2324 260 49916
27-Apr 1739 333 32003
28-Apr 2019 382 57272
29-Apr 2086 323 63827
30-Apr 1872 285 68456
01-May 1965 269 74208
02-May 1900 474 55412
03-May 1389 174 44935
04-May 1221 195 37631
05-May 1075 236 55263
06-May 1444 369 64263
07-May 1401 274 70359
08-May 1327 243 63775
09-May 1083 194 69171
10-May 802 165 51678
11-May 744 179 40740
12-May 1402 172 67003
13-May 888 195 61973
14-May 992 262 71876
15-May 789 242 68176
16-May 875 153 69179
17-May 675 145 60101
18-May 451 99 36406
19-May 813 162 63158
20-May 665 161 67195
21-May 642 156 71679
22-May 652 130 75380
23-May 669 119 72410
24-May 531 50 55824
25-May 300 92 35241
26-May 397 78 57674
27-May 584 117 67324
28-May 593 70 75893
29-May 516 87 72135
30-May 416 111 69342
31-May 333 75 54118
01-Jun 200 60 31394
02-Jun 319 55 52159
03-Jun 322 71 37299
04-Jun 177 88 49953
05-Jun 519 85 65028
06-Jun 270 72 72485
07-Jun 197 53 49478
08-Jun 280 65 27112
09-Jun 283 79 55003
10-Jun 202 71 62699
11-Jun 380 53 62472
12-Jun 163 56 70620
13-Jun 347 78 49750
14-Jun 337 44 56527
15-Jun 301 26 28107
16-Jun 210 34 46882
17-Jun 329 43 77701
18-Jun 332 66 58154
19-Jun 251 47 57541
20-Jun 264 49 54722
21-Jun 224 24 40545
22-Jun 221 23 28972
23-Jun 113 18 40485
24-Jun 190 30 53266
25-Jun 296 34 56061
26-Jun 255 30 52768
27-Jun 175 8 61351
28-Jun 174 22 37346
29-Jun 126 6 27218
30-Jun 142 23 48273
01-Jul 182 21 55366
02-Jul 201 30 53243
03-Jul 223 15 50096
04-Jul 235 21 52011
05-Jul 192 7 37462
06-Jul 208 8 22166
07-Jul 137 30 43219
08-Jul 193 15 50443
09-Jul 214 12 52552
10-Jul 276 12 47953
11-Jul 188 7 45931
12-Jul 234 9 38259
13-Jul 169 13 23933
14-Jul 114 17 41867
15-Jul 162 13 48449
16-Jul 230 20 50432
17-Jul 231 11 50767
18-Jul 249 14 48265
19-Jul 218 3 35525
20-Jul 190 13 24253
21-Jul 128 15 43110
22-Jul 280 9 49318
23-Jul 306 10 60311
24-Jul 252 5 53334
25-Jul 273 5 51671
26-Jul 252 5 40526
27-Jul 170 5 25551
28-Jul 181 11 48170
29-Jul 289 6 56018
30-Jul 382 3 61858
31-Jul 379 9 60944
01-Aug 295 5 60383
02-Aug 238 8 43269
03-Aug 159 12 24036
04-Aug 190 5 43788
05-Aug 384 10 56451
06-Aug 401 6 58673
07-Aug 552 3 59196
08-Aug 347 13 53298
09-Aug 463 2 37637
10-Aug 259 4 26432
11-Aug 412 6 40642
12-Aug 476 10 52658
13-Aug 522 6 51188
14-Aug 574 3 46723
15-Aug 627 4 53123
16-Aug 479 4 36807
17-Aug 320 4 30666
18-Aug 401 5 53976
19-Aug 642 7 71095
20-Aug 840 6 77442
21-Aug 947 9 71996
22-Aug 1071 3 77674
23-Aug 1209 7 67371
24-Aug 952 4 45914
25-Aug 876 4 72341
26-Aug 1365 13 93529
27-Aug 1409 5 94024
28-Aug 1462 9 97065
29-Aug 1444 1 99108
30-Aug 1365 4 81723
31-Aug 999 6 58518
01-Sep 984 8 81050
02-Sep 1332 6 102959
03-Sep 1402 10 92790
04-Sep 1738 11 113085
05-Sep 1700 16 107658
06-Sep 1303 7 76856
07-Sep 1107 12 52553
08-Sep 1366 10 92403
09-Sep 1434 14 95990
10-Sep 1597 10 94186
11-Sep 1616 10 98880
12-Sep 1499 6 92706
13-Sep 1458 7 72143
14-Sep 1008 14 45309
15-Sep 1229 9 80517
16-Sep 1450 12 100607
17-Sep 1585 13 101773
18-Sep 1906 10 99839
19-Sep 1638 24 103223
20-Sep 1587 15 83428
21-Sep 1349 17 55862
22-Sep 1392 14 87303
23-Sep 1640 20 103696
24-Sep 1786 23 108019
25-Sep 1912 20 107269
26-Sep 1869 17 104387
27-Sep 1766 17 87714
28-Sep 1493 16 51109
29-Sep 1647 24 90185
30-Sep 1851 19 105236
01-Oct 2548 24 118236
02-Oct 2498 23 120301
03-Oct 2844 27 118932
04-Oct 2578 18 92714
05-Oct 2257 16 60241
06-Oct 2676 28 99742
07-Oct 3678 31 125314
08-Oct 4458 22 128098
09-Oct 5372 28 129471
10-Oct 5724 29 133084
11-Oct 5456 26 104658
12-Oct 4616 39 85442
13-Oct 5901 41 112544
14-Oct 7331 43 152196
15-Oct 8803 83 162932
16-Oct 10010 55 150377
17-Oct 10925 47 165837
18-Oct 11704 69 146541
19-Oct 9335 73 98862
20-Oct 10874 89 144737
21-Oct 15198 127 177848
22-Oct 16079 136 170392
23-Oct 19139 91 182032
24-Oct 19644 151 177669
25-Oct 21268 128 161880
26-Oct 17007 141 124686
27-Oct 21991 221 174398
28-Oct 24989 205 198952
29-Oct 26826 217 201452
30-Oct 31082 199 215085
31-Oct 31756 297 215886
01-Nov 29907 208 183457
02-Nov 22250 233 135731
03-Nov 28242 353 182287
04-Nov 30547 352 211831
05-Nov 34498 428 219884
06-Nov 37807 446 234245
07-Nov 39809 425 231673
08-Nov 32614 331 191144
09-Nov 25263 356 147725
10-Nov 35098 580 217758
11-Nov 32960 623 225640
12-Nov 37978 636 234672
13-Nov 40896 550 254908
14-Nov 37253 544 227695
15-Nov 33977 546 195275
16-Nov 27354 504 152663
17-Nov 32188 731 208458
18-Nov 34283 753 234834
19-Nov 36173 653 250186
20-Nov 37239 699 238077
21-Nov 34767 692 237225
22-Nov 28334 562 188747
23-Nov 22925 630 148945
24-Nov 23231 853 188659
25-Nov 25851 722 230007
26-Nov 28993 822 232711
27-Nov 28344 827 222803
28-Nov 26321 686 225940
29-Nov 20647 541 130524
30-Nov 16374 672 130524
01-Dec 19350 785 182100
02-Dec 20703 684 207143
03-Dec 23236 993 220047
04-Dec 24099 814 212741
05-Dec 21052 662 194984
06-Dec 18846 564 163550
07-Dec 13612 528 111217
08-Dec 14733 634 149232
09-Dec 12652 499 118475
10-Dec 16887 887 171586
11-Dec 18550 761 190416
12-Dec 19738 649 196439
13-Dec 17818 484 152697
14-Dec 11965 491 103584
15-Dec 14714 846 164431
16-Dec 17431 680 199489
17-Dec 18136 683 185320
18-Dec 17989 674 179800
19-Dec 16306 553 176185
20-Dec 15104 352 137420
21-Dec 10860 415 87889
22-Dec 13294 628 157705
23-Dec 14521 553 183864
24-Dec 18040 505 193777
25-Dec 19037 459 152334
26-Dec 10429 261 81564
27-Dec 8909 305 59879
28-Dec 8583 445 68681
29-Dec 11212 659 128740
30-Dec 16202 575 169045
31-Dec 23476 555 186004
01-Jan 22205 462 157524
02-Jan 11831 364 67174
03-Jan 14243 347 102974
04-Jan 10797 348 77993
05-Jan 15373 649 135106
06-Jan 20331 548 121275
07-Jan 18016 414 140267
08-Jan 17531 620 172119
09-Jan 19976 483 139758
10-Jan 18625 361 139758
11-Jan 12532 448 91656
12-Jan 14241 616 141641
13-Jan 15771 507 175429
14-Jan 17244 522 160585
15-Jan 16146 477 273506
16-Jan 16309 475 261404
17-Jan 12545 377 211078
18-Jan 8824 377 158674
19-Jan 10494 603 254070
20-Jan 13548 524 279762
21-Jan 14078 521 267567
22-Jan 13633 472 264728
23-Jan 13330 488 286331
24-Jan 11627 299 216211
25-Jan 8552 420 126931
26-Jan 10580 541 256287
27-Jan 15192 467 293770
28-Jan 14361 492 275579
29-Jan 13572 477 268750
30-Jan 12712 421 298010
31-Jan 11252 237 213364
01-Feb 7916 329 142419
02-Feb 9653 499 244429
03-Feb 13186 476 279307
04-Feb 13654 421 270142
05-Feb 14215 377 270507
06-Feb 13441 385 282407
07-Feb 11640 270 206789
08-Feb 7952 307 144270
09-Feb 10621 422 274263
10-Feb 12947 336 310994
11-Feb 15131 391 292533
12-Feb 13899 316 287619
13-Feb 13524 311 290534
14-Feb 11061 221 205642
15-Feb 7333 258 179278
16-Feb 10378 336 274019
17-Feb 12067 369 294411
18-Feb 13753 347 288458
19-Feb 15462 348 297128
20-Feb 14929 251 306078
21-Feb 13439 232 250986
22-Feb 9615 274 170672
23-Feb 13292 356 303850
24-Feb 16409 318 340247
25-Feb 19875 308 353704
26-Feb 20485 253 325404
27-Feb 18901 280 323047
28-Feb 17447 192 257024
01-Mar 13094 246 170633
02-Mar 17039 343 335983
03-Mar 20864 347 358884
04-Mar 22839 339 339635
05-Mar 24028 297 378463
06-Mar 23600 307 355024
07-Mar 20745 207 271336
08-Mar 13878 318 184684
09-Mar 19615 376 345972
10-Mar 22385 332 361040
11-Mar 25639 373 372217
12-Mar 26793 380 369636
13-Mar 26051 317 372944
14-Mar 21300 264 273966
15-Mar 15247 354 179015
16-Mar 20377 502 369375
17-Mar 23025 431 369084
18-Mar 24907 423 353737
19-Mar 25816 386 364822
20-Mar 23718 401 354480
21-Mar 20149 300 277086
22-Mar 13820 386 169196
23-Mar 18744 551 335189
24-Mar 21239 460 363767
25-Mar 23798 460 349472
26-Mar 23982 457 354982
27-Mar 23839 380 357154
28-Mar 19611 297 272630
29-Mar 12954 417 156692
30-Mar 16000 529 301451
31-Mar 22439 467 351221
01-Apr 23634 501 356085
02-Apr 21918 481 331154
03-Apr 21253 376 359214
04-Apr 18025 326 250933
05-Apr 10676 296 102795
06-Apr 7745 421 112962
07-Apr 13696 627 339939
08-Apr 17207 487 362162
09-Apr 18922 718 349003
10-Apr 17558 344 334862
11-Apr 15737 331 253100
12-Apr 9781 358 190635
13-Apr 13439 476 304990
14-Apr 16157 469 334766
15-Apr 16954 380 319633
16-Apr 15937 429 327704
17-Apr 15364 310 331734
18-Apr 12693 251 230116
19-Apr 8859 317 146728
20-Apr 12066 392 294045
21-Apr 13658 365 350034
22-Apr 16229 361 364804
23-Apr 14758 344 315700
24-Apr 13816 324 320780
25-Apr 13154 218 239482
26-Apr 8438 303 145819
27-Apr 10401 374 302734
28-Apr 13379 345 336336
29-Apr 14319 289 330075
30-Apr 13445 264 338771
01-May 12962 226 378202
02-May 9146 144 156872
03-May 5945 256 121829
04-May 9110 305 315506
05-May 10576 267 327169
06-May 11802 258 324640
07-May 10552 207 328612
08-May 10173 224 338436
09-May 8289 139 226006
10-May 5077 198 130000
11-May 6942 251 286428
12-May 7849 262 306744
13-May 8080 201 287026
14-May 7560 182 298186
15-May 6654 136 294686
16-May 5752 93 202573
17-May 3452 140 118924
18-May 4446 201 262864
19-May 5501 149 287256
20-May 5738 164 251037
21-May 5215 133 269744
22-May 4715 125 286603
23-May 3994 72 179391
24-May 2486 110 107481
25-May 3222 166 252646
26-May 3933 121 260962
27-May 4146 171 243967
28-May 3738 126 249911
29-May 3350 83 247330
30-May 2947 44 164495
31-May 1820 82 86977
01-Jun 2482 93 221818
02-Jun 2892 62 226272
03-Jun 1967 59 97633
04-Jun 2555 73 220939
05-Jun 2436 57 238632
06-Jun 2272 51 149958
07-Jun 1271 65 84567
08-Jun 1895 102 220917
09-Jun 2198 77 218738
10-Jun 2070 88 188120
11-Jun 1900 69 217610
12-Jun 1723 52 212966
13-Jun 1390 26 134136

Table S2.

Week definition with starting and ending date

Week Starting Date Ending Date
W1 02/03/2020 08/03/2020
W2 09/03/2020 15/03/2020
W3 16/03/2020 22/03/2020
W4 23/03/2020 29/03/2020
W5 30/03/2020 05/04/2020
W6 06/04/2020 12/04/2020
W7 13/04/2020 19/04/2020
W8 20/04/2020 26/04/2020
W9 27/04/2020 03/05/2020
W10 04/05/2020 10/05/2020
W11 11/05/2020 17/05/2020
W12 18/05/2020 24/05/2020
W13 25/05/2020 31/05/2020
W14 01/06/2020 07/06/2020
W15 08/06/2020 14/06/2020
W16 15/06/2020 21/06/2020
W17 22/06/2020 28/06/2020
W18 29/06/2020 05/07/2020
W19 06/07/2020 12/07/2020
W20 13/07/2020 19/07/2020
W21 20/07/2020 26/07/2020
W22 27/07/2020 02/08/2020
W23 03/08/2020 09/08/2020
W24 10/08/2020 16/08/2020
W25 17/08/2020 23/08/2020
W26 24/08/2020 30/08/2020
W27 31/08/2020 06/09/2020
W28 07/09/2020 13/09/2020
W29 14/09/2020 20/09/2020
W30 21/09/2020 27/09/2020
W31 28/09/2020 04/10/2020
W32 05/10/2020 11/10/2020
W33 12/10/2020 18/10/2020
W34 19/10/2020 25/10/2020
W35 26/10/2020 01/11/2020
W36 02/11/2020 08/11/2020
W37 09/11/2020 15/11/2020
W38 16/11/2020 22/11/2020
W39 23/11/2020 29/11/2020
W40 30/11/2020 06/12/2020
W41 07/12/2020 13/12/2020
W42 14/12/2020 20/12/2020
W43 21/12/2020 27/12/2020
W44 28/12/2020 03/01/2021
W45 04/01/2021 10/01/2021
W46 11/01/2021 17/01/2021
W47 18/01/2021 24/01/2021
W48 25/01/2021 31/01/2021
W49 01/02/2021 07/02/2021
W50 08/02/2021 14/02/2021
W51 15/02/2021 21/02/2021
W52 22/02/2021 28/02/2021
W53 01/03/2021 07/03/2021
W54 08/03/2021 14/03/2021
W55 15/03/2021 21/03/2021
W56 22/03/2021 28/03/2021
W57 29/03/2021 04/04/2021
W58 05/04/2021 11/04/2021
W59 12/04/2021 18/04/2021
W60 19/04/2021 25/04/2021
W61 26/04/2021 02/05/2021
W62 03/05/2021 09/05/2021
W63 10/05/2021 16/05/2021
W64 17/05/2021 23/05/2021
W65 24/05/2021 30/05/2021
W66 31/05/2021 06/06/2021
W67 07/06/2021 13/06/2021

Statistical Analysis

Numbers of cases, deaths, and tests were grouped in a week-based manner (Table S3). The average daily values (also denoted as weekly-averaged values) of cases and deaths were obtained by dividing the total weekly number by seven.

Table S3.

Cases and deaths per week of Phase 1 (blue, W1-W17) and Phase 2 (green, W32-W67). Average daily values were obtained dividing the total weekly number of cases/deaths by seven

Week Average number of cases Average number of deaths
W1 811 46
W2 2482 206
W3 4913 524
W4 5500 758
W5 4466 730
W6 3916 573
W7 3230 537
W8 2672 426
W9 1853 320
W10 1193 239
W11 909 193
W12 632 125
W13 448 90
W14 286 69
W15 285 64
W16 273 41
W17 203 24
W18 186 18
W19 207 13
W20 196 13
W21 240 9
W22 276 7
W23 357 7
W24 478 5
W25 776 6
W26 1268 6
W27 1351 9
W28 1440 10
W29 1486 14
W30 1673 18
W31 2208 22
W32 4232 26
W33 8470 54
W34 15934 114
W35 26223 213
W36 32252 367
W37 34775 548
W38 32905 656
W39 25187 726
W40 20523 739
W41 16284 635
W42 15949 611
W43 13584 447
W44 15393 487
W45 17236 489
W46 14970 489
W47 12219 469
W48 12317 436
W49 11958 394
W50 12162 329
W51 12480 306
W52 16575 283
W53 20316 298
W54 22237 337
W55 21891 400
W56 20719 427
W57 19460 442
W58 14506 461
W59 14332 382
W60 13220 332
W61 11727 278
W62 9492 237
W63 6845 189
W64 4723 141
W65 3403 117
W66 2346 68
W67 1778 68

Following our previous study of the time evolution of COVID-19 lethality during the first wave (8,9), our analysis included:

  1. Identification of the different phases of the epidemic. On the basis of the inspection of the cases and deaths curves, we conventionally set the end of the first phase on June 28th, 2020, latest day of week 17 (W17); hence, the first phase (also referred to as Phase 1) lasted 17 weeks (119 days). Similarly, the beginning of the second phase (Phase 2) was set on October 5th, 2020, first day of W32; thus, the second phase has lasted 36 weeks so far (252 days).

  2. Dissection of the data and analytical modeling of the detected cases/deaths: we first described the lockdown-driven fall of Phase 1 and the initial rise of Phase 2 with a decreasing exponential and a sigmoidal function, respectively. Exponential and sigmoidal functions with calibrated parameters were then used for the falls and rises of all other curves.

  3. The temporal shift of the cases/deaths curves was obtained by examining the derived functions. In addition, we performed a sensitivity analysis relying on the sum of squared residuals (SSR) in order to evaluate the quality of the fitting between the aforementioned curves upon specific shifts.

  4. Depending on the detected shift at different phases/subphases of the pandemic, the WLR values were calculated by dividing the average daily number of deaths of a given week (Wi) by the average daily number of cases of one week (Wi-1), two weeks (Wi-2), or three weeks (Wi-3) before. In detail, the WLR values were computed applying a 1-week, 2-week, and 3-week shift between positive test and death in the time intervals W1-W33, W34-W41, and W42-W67, respectively.

In order to detect the temporal link between positive testing to the virus and death (as done for Phase 1 (8)), we partitioned Phase 2 into three distinct subphases, referred to as 2.1, 2.2, and 2.3, defined on the basis of the peaks detected in the cases/deaths curves on Nov 13th/Dec 3rd, 2020, Jan 6th/8th, 2021, and Mar 12th/Apr 9th, 2021 (Figures 1 and S1), respectively.

Figure 1.

Figure 1.

Evolution of the weekly-averaged (A) cases (positive tests) and (B) deaths. Weeks have been numbered according to Table S2.

Figure S1.

Figure S1.

Daily evolutions of (A) cases (positive tests) and (B) deaths in the time interval March 2nd, 2020 - June 13th, 2021.

In our post-hoc sensitivity analysis, the application of the temporal 1-week shift scheme – successfully applied to analyze Phase 1 (8) (Figure 2A) – produced a very poor fitting between the cases and deaths curves of Phase 2 (Figure 2B). Better fittings were obtained by applying shifts of two or three weeks to the curve of the cases (Figure 2C and 2D). A closer inspection of the fitting clearly indicates that a unique week shift scheme cannot account for the complexity of Phase 2.

Figure 2.

Figure 2.

Comparison of the evolution of the weekly cases (black) and deaths (red) upon normalization of the curves in (A) Phase 1 (W1-W17) and (B-D) Phase 2 (W32-W67) of the pandemic. The normalization was performed by dividing the actual values by the maximum of each ensemble. The curve of cases is 1-week (A, B), 2-week (C), 3-week (D) shifted ahead.

The analytical modeling of the weekly-averaged cases/deaths in Phase 2 was performed as follows. As a first step:

  • - the lockdown-driven fall of the deaths of Phase 1 was favorably described with a decreasing exponential (Figure S3) graphic file with name ACTA-92-395-eq001.jpg the time constant Wfd of which was calibrated to 3.8 weeks to obtain the best agreement between (1) and the real data.

  • - the initial deaths rise of Subphase 2.1 was described with the sigmoidal function (Figure S3) graphic file with name ACTA-92-395-eq002.jpg where the time constant Wr and power factor nr were adjusted to 4.1 weeks and 2.5, respectively (Figure S3); deaths(W40) represents the peak value of this subphase.

    Subsequently, exponential and sigmoidal functions with the same values for Wfd, Wr, and nr were adopted also to model the deaths falls of Subphases 2.1, 2.2, 2.3, as well as the rises of Subphases 2.2 and 2.3, respectively (Figure 3A). As an example, the fall of Subphase 2.1 was described with graphic file with name ACTA-92-395-eq003.jpg and the rise of Subphase 2.2 with graphic file with name ACTA-92-395-eq004.jpg Crd2.2 being a fitting parameter tuned to ensure the best matching between the overall model and real data (Figure 3B).

    A similar strategy was used to model the evolution of the weekly-averaged cases. First, it was noted that the rise of Subphase 2.1 was accurately described by the same sigmoidal function (and same parameters) exploited for the deaths (Figure 4A), i.e., graphic file with name ACTA-92-395-eq005.jpg cases(W37) being the peak reached during this subphase. Equation (2) was also used to model the rises of cases of Subphases 2.2 and 2.3 (Figure 4A); as an example, graphic file with name ACTA-92-395-eq006.jpg was employed for Subphase 2.2, Crc2.2 being a fitting parameter.

    A reasonably faster time constant Wfc=3.2 weeks was adopted in the decreasing exponentials used to describe the falls of cases in Subphases 2.1, 2.2, and 2.3 (Figure 4A); as far as Subphase 2.1 is concerned, the exponential function is graphic file with name ACTA-92-395-eq007.jpg

Figure S3.

Figure S3.

Modeling of the lockdown-driven fall of Phase 1 and the rise of Subphase 2.1 of the curve of deaths with a decreasing exponential (time constant 3.8) and a sigmoidal (exponent 2.5 and time constant 4.1) function, respectively.

Figure 3.

Figure 3.

(A) Modeling of the three subphases of the curve of deaths of Phase 2 with mathematical functions. For the rises, sigmoidal functions making use of exponent 2.5 and time constant 4.1 were exploited. The time constant 3.8 calibrated for the fall of deaths occurring in Phase 1 was also employed for the falls of the three subphases of Phase 2. (B) Model (sum of the 3 modeled subphases) of Phase 2 superimposed to the real data.

Figure 4.

Figure 4.

(A) Modeling of the three subphases of Phase 2 of the curve of cases with mathematical functions. For the rises, sigmoidal functions making use of exponent 2.5 and time constant 4.1 were exploited. The time constant 3.2 was employed for the falls of the three Phase 2 subphases. (B) Model (sum of the 3 modeled subphases) superimposed to the real data.

The deconvolution of the deaths/cases curves also provides a measure of the temporal shift between the positive testing and the fatal event. A comparison of the equations used to fit the experimental data indicates that the rise of the deaths in Subphase 2.1 is shifted two weeks ahead with respect to the corresponding testing: weeks W32 and W30 are indeed used to identify the rise onsets of deaths and cases, respectively. On the other hand, for the subsequent subphases the equations suggest a 3-week shift; as far as Subphase 2.2 is concerned, weeks W38 and W41 are adopted for cases and deaths. These results are in line with those obtained through a comparative analysis performed by shifting the normalized curve of daily cases with respect to the deaths counterpart and calculating the SSR between them; this approach was also exploited to examine Phase 1 in (8).

Based on the variable shifts between the curves of deaths/cases detected throughout the pandemic, we adapted the definition of the WLR previously introduced (8) by alternatively considering a 1-week, a 2-week, or a 3-week shift. A regression analysis was performed on the WLR values in the weeks W50-W67 to quantify its decrease. 95% confidence intervals (95% CI) were computed according to a Poisson approximation. The significance level (0.05) of the decrease was assessed by calculating the p-value. Data were analyzed with MATLAB R2014b and R statistical software v. 4.0.0 (11,12).

The study did not involve participants and information were gathered from freely accessible public databases, and data were analyzed in aggregated form and without any identifier. Therefore, no ethical approval was required for this research. The analyses adhere to the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) (13).

Results

Comparative analysis of the evolution of cases and deaths

The inspection of the daily deaths/cases curves (Figures 1 and S1) clearly indicates that the country suffered from two main outbreaks (here denoted as Phase 1 and Phase 2). The first started at the end of February 2020 and ended in the summer of the same year. Moreover, starting from the fall 2020 a second remarkable increase of both cases and deaths was experienced. Although this second phase is progressively regressing, it is still ongoing (June 2021). Notably, the maxima of the deaths curve are pretty similar in the two phases while the maximum of the cases is significantly higher in the second phase compared to the first one.

As previously explained, the application of the temporal 1-week shift scheme that was successfully exploited to analyze Phase 1 (8) (Figure 2A) produced a very poor fitting of the curves of Phase 2 (Figure 2B). Better fittings are obtained by using shifts of two or three weeks to the curve of the cases (Figure 2C and 2D). A closer inspection of the fitting clearly indicates that a unique shift scheme cannot account for the complexity of Phase 2. This observation is not surprising considering the remarkable time span of Phase 2 (~9 months). A similar conclusion is reached when the SSR between the normalized daily cases/deaths is calculated upon the systematic shifts of the curve of the cases of Phase 2. As shown in Figure S2, the SSR values present a marked weekly periodicity due to the daily dependence of testing and death registrations. Interestingly, two nearly identical global minima corresponding to shifts of either 13 or 20 days are evident. In this scenario, considering the complexity of Phase 2, we deconvolute the global cases/deaths curves by identifying the underlying curves corresponding to the three subphases (2.1, 2.2., and 2.3) (Figure 3A and Figure 4A). This was done by noticing that the ascending parts of the curves can be described by sigmoidal increases whereas the descending regions are characterized by exponential decreases (see Methods for details). In this framework, the main parameter for the exponential function was derived from the fitting of deaths of the descendent region of Phase 1.

Figure S2.

Figure S2.

Sum of squared residuals (SSR) as a function of day shift of the curves in Phase 2 (W32-W67). The normalized curve of the daily cases is shifted ahead with respect to the normalized curve of the daily deaths.

The superposition of the deconvoluted curves (Figure 3B and Figure 4B) shows a remarkable agreement with the real cases/deaths. The only significant discrepancies are observed in the time interval W42-W45 that corresponds to mid-December – mid-January when, due to the holiday season, the recording of cases and deaths was occasionally postponed. Such a deconvolution also provides a measure of the temporal shift between the positive testing and the fatal event. An inspection of the equations used to fit the experimental data indicates that the rise of the deaths in Subphase 2.1 is shifted by two weeks from the corresponding positive testing; in the fitting curve, the parameter W32 or W30 is indeed present for deaths and cases, respectively. On the other hand, for the subsequent weeks the equations suggest a 3-week shift since the parameter in the equations is either W41 (deaths) or W38 (cases). These observations are confirmed by the indications provided by the SSR analysis described above.

Weekly Lethality Rate

Based on the variable shifts between the curves of deaths/cases detected throughout Phase 2, we adapted the definition of the WLR previously introduced (8) by alternatively considering a single week (from W2 to W33) shift, a 2-week shift (from W34 to W41), or a 3-week (from W42 to W67) shift. As shown in Figure 5 and Table S4, we observed significant changes of this parameter in the different stages of the pandemic. In particular, the value of WLR was grossly overestimated (~13.5%) in Phase 1 (8). This is likely due to the severe underestimation of the cases at that time. A WLR value of about 2.6% was observed in most of Phase 2. Interestingly, a slow but significant reduction of this parameter has taken place in the last weeks (W50-W67; February 8th – June 13th, 2021). In particular, at W67 the WLR assumes a value (1.4%) that is almost halved when compared to the nearly constant one detected in the period W34-W49.

Figure 5.

Figure 5.

Weekly lethality rate (WLR) evolution in the overall pandemic. The WLR values were calculated applying a 1-week (black and grey), 2-week (red), and 3-week (green) shift between positive test and death in the time intervals W2-W33, W34-W41, and W42-W67, respectively. Values computed for the weeks (W14-W33, W66-W67) with less than 70 weekly-averaged deaths are in light grey. The average WLR value (2.56%) detected in the time interval W34-W49 is shown as a dashed line. The linear regression analysis of the WLR values in the weeks W50-W67 provides a correlation coefficient R=-0.95 (p-value<10-5). The regression line (y = 7.4091 - 0.093675 x) is shown in red.

Table S4.

Weekly lethality rate (WLR) values with 95% confidence intervals (95%CI). The WLR values were calculated applying a 1-week, 2-week, and 3-week shift between positive test and death in the time intervals W1-W33, W34-W41, and W42-W67, respectively. WLR values were calculated by dividing the average daily number of deaths of a given week (Wi) by the average daily number of cases of one week (Wi-1), two weeks (Wi-2), or three weeks (Wi-3) before

Week WLR 1-week shift Week WLR 2-week shift Week WLR 3-week shift
95% CI 95% CI 95% CI
W2 25.43 (24.1 – 26.8) W34 2.68 (2.5 – 2.9) W42 2.43 (2.4 – 2.5)
W3 21.10 (20.4 – 21.8) W35 2.51 (2.4 – 2.6) W43 2.18 (2.1 – 2.3)
W4 15.42 (15.0 – 15.8) W36 2.30 (2.2 – 2.4) W44 2.99 (2.9 – 3.1)
W5 13.27 (12.9 – 13.6) W37 2.09 (2.0 – 2.2) W45 3.07 (3.0 – 3.2)
W6 12.83 (12.4 – 13.2) W38 2.03 (2.0 – 2.1) W46 3.60 (3.5 – 3.7)
W7 13.72 (13.3 – 14.1) W39 2.09 (2.0 – 2.1) W47 3.05 (2.9 – 3.2)
W8 13.20 (12.7 – 13.7) W40 2.25 (2.2 – 2.3) W48 2.53 (2.4 – 2.6)
W9 11.98 (11.5 – 12.5) W41 2.52 (2.4 – 2.6) W49 2.63 (2.5 – 2.7)
W10 12.92 (12.3 – 13.6) W50 2.69 (2.6 – 2.8)
W11 16.14 (15.3 – 17.0) W51 2.48 (2.4 – 2.6)
W12 13.78 (12.9 – 14.7) W52 2.37 (2.3 – 2.5)
W13 14.24 (13.2 – 15.4) W53 2.45 (2.3 – 2.6)
W14 15.42 (14.1 – 16.9) W54 2.70 (2.6 – 2.8)
W15 22.25 (20.2 – 24.4) W55 2.41 (2.3 – 2.5)
W16 14.51 (12.9 – 16.3) W56 2.10 (2.0 – 2.2)
W17 8.63 (7.4 – 10.1) W57 1.99 (1.9 – 2.1)
W18 8.64 (7.2 – 10.3) W58 2.10 (2.0 – 2.2)
W19 7.15 (5.8 – 8.8) W59 1.84 (1.8 – 1.9)
W20 6.28 (5.1 – 7.7) W60 1.70 (1.6 – 1.8)
W21 4.52 (3.5 – 5.8) W61 1.92 (1.8 – 2.0)
W22 2.80 (2.1 – 3.7) W62 1.65 (1.6 – 1.7)
W23 2.64 (2.0 – 3.5) W63 1.43 (1.4 – 1.5)
W24 1.48 (1.0 – 2.0) W64 1.20 (1.1 – 1.3)
W25 1.22 (0.9 – 1.7) W65 1.24 (1.2 – 1.3)
W26 0.74 (0.5 – 1.0) W66 1.00 (0.9 – 1.1)
W27 0.72 (0.6 – 0.9) W67 1.45 (1.3 – 1.6)
W28 0.73 (0.6 – 0.9)
W29 0.96 (0.8 – 1.2)
W30 1.23 (1.0 – 1.5)
W31 1.29 (1.1 – 1.5)
W32 1.16 (1.0 – 1.3)
W33 1.27 (1.1 – 1.4)

Discussion

One of the most striking and worrying features of the COVID-19 pandemic is its unpredictable evolution: with the exception of an extremely limited number of nations that have been able to control the infections, the vast majority of the countries have suffered from phases characterized by a high COVID-19 burden that was alternated with time periods in which the pandemic was essentially under control. This articulated evolution has also been experienced in Italy, the center of the first main outbreak across Western countries. In the initial stage of the pandemic (February – June 2020), quite strong measures were taken by the governmental authorities to severely limit the mobility of people and therefore the diffusion of the infection (2,8). Despite the gross underestimation of cases in the early months of the outbreak (due to the emergency phase and a low capacity of case detecting), the enforcement of severe lockdown restrictions contributed to the clear-cut shape of the curves, with an ascending curve followed by a monotonic descending one (Figure 1). The analogous trends displayed by the curves reporting cases and deaths prompted us to search for a temporal link between them. A remarkable good fitting between these two profiles was obtained when the curve of the cases was shifted by one week (8). The well-defined quantification of this temporal link provided us the opportunity to define a time-dependent WLR that was nearly constant in the first months of the pandemic. The inspection of the WLR profile indicates that, after assuming rather large values (~13.5%) in Phase 1 due to the underestimation of cases, it decreased to very low values (below 1%) during the summer of 2020 (Figure 5). Although the marked reduction in the number of cases/deaths observed in this period makes the calculated WLR less reliable, its drop may be ascribed to different factors including the lockdown measures, the seasonality of viral respiratory diseases, and an increased virus circulation amongst young people who are less susceptible to severe and fatal COVID-19 outcomes (14,15). Therefore, after the initial outbreak and the summer months, when the infections were essentially under control, from fall 2020 Italy suffered a second phase (Phase 2) of the pandemic that is still ongoing. Differently from the first, Phase 2 has been characterized by an intricate evolution with multiple rises and decreases of the infections. On the basis of the peaks that we observed in the curves of both cases and deaths, we were able to identify and model three distinct subphases. As a whole, the shape of the Phase 2 curve mirrored the differences in virus circulation and type of restrictive public health measures compared to Phase 1. From an epidemiological standpoint, in the first half of 2020, the major spread of SARS-CoV-2 was limited to northern regions of the country, which registered the biggest COVID-19 outbreak in terms of both cases and death toll (16); from September 2020, the virus has been circulating across the entire country (14). Again, in order to reduce the social and economic consequences of protracted lockdown restrictions, governmental authorities adopted less-stringent limiting measures, the impact of which was reflected in the curves. A system of region-based risk levels was implemented, which allowed the easing of measures according to a set of indicators (for instance, number of cases and deaths, number of intensive care unit [ICU] admissions, percentage of occupied ICU beds, etc.), with different extents of SARS-CoV-2 circulation across regions and weeks (14).

Interestingly, despite the heterogeneity of the data that are separately collected in the twenty-one regions/territories of the country and the complexity of Phase 2, we could quantify the temporal link between cases and deaths. Notably, the shift between the positive testing and the fatal event is longer than that observed in Phase 1 (one week) and is progressively increasing during Phase 2 (two or three weeks). This difference can be ascribed to the improved timeliness of the testing, which was only reserved to people displaying symptoms in Phase 1 and, possibly, to some improvement in the therapeutic interventions that delayed the death in Phase 2. Moreover, the identification of this temporal link gave us the opportunity to evaluate the lethality attributable to COVID-19 in Italy during the whole epidemic period, from March 2020 to June 2021, using complete epidemiological data of SARS-CoV-2 spread in the country.

A significant increase of the WLR took place in October 2020, concurrently with a new increase of the virus spread and its following circulation in susceptible populations, like elder individuals or people in fragile states (14,15). From the beginning of Phase 2 to the beginning of February 2021 the WLR assumed a rather constant value (~2.6%) (Figure 5). Starting from mid-February 2021 (W51), the WLR is significantly decreasing. It is important to note in this time interval the WLR practically halved from 2.6 to 1.3%, the value detected at the beginning of June 2021. Notably, this period also coincides with the progressive increase of the vaccination coverage in Italy, primarily in at-risk and susceptible subjects, with a consequent positive impact on COVID-19 burden and lethality reduction (7). Further research is needed to better investigate the impact of vaccines and vaccination campaign on SARS-CoV-2 diffusion and lethality.

Some limitations of our study should be acknowledged. First, as for our previous analysis of lethality during the first epidemic wave (8), the research included information measured through surveillance systems where data were provided in aggregated form and without any case stratification; thus, it was not possible to evaluate uncertainty sources and adjust results for potential independent predictors of death, but this research was intended as a straightforward strategy to assess the time-trend of the proportion of cases who died from the disease. Second, the WLR uses the number of subjects that tested positive as population (denominator), thus being influenced by the number of tests performed on a certain time-point. However, the combination of data on a weekly-aggregated manner greatly reduced possible differences across different week-days. Lastly, even if the 1- to 2-week and 2- to 3-week shifts were based on static denominators, the WLR calculated a ratio representing relative rates of deaths which reflect analytical expressions of lethality proxy over time.

In conclusion, our study provides interesting insights into the evolution of the COVID-19 pandemic in Italy by highlighting some distinctive features, in terms of trend complexity of the lethality rate in the different phases of the pandemic. Our approach also documented the impact of the public health measures on SARS-CoV-2 spread and associated lethality, also highlighting the possible positive effect of vaccination efforts, but more studies assessing this hypothesis should be implemented in the near future. The application of the proposed approach could help examine data from other contexts, allowing comparison with the lethality associated with SARS-CoV-2 in other countries.

Funding:

This research was funded by Regione Campania project “RicErCa e sviluppO VERsus COVID19 in Campania RECOVER-COVID19” (POR FESR CAMPANIA 2014-2020 - Asse III Obiettivo Specifico 1.3 - Azione 1.3.1).

Conflicts of Interest:

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. In: StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2021 Apr 20. Features, Evaluation, and Treatment of Coronavirus (COVID-19) [PubMed] [Google Scholar]
  2. Ferrara P, Albano L. COVID-19 and healthcare systems: what should we do next? Public Health. 2020;185:1–2. doi: 10.1016/j.puhe.2020.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100. doi: 10.1016/j.biochi.2020.09.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int. (Last accessed on July 10, 2021) [Google Scholar]
  5. COVID-19 coronavirus pandemic. Available online: https://www.worldometers.info/coronavirus/italy. (Last accessed on July 10, 2021) [Google Scholar]
  6. Chaqroun A, Hartard C, Schvoerer E. Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants. Viruses. 2021;13(6):1171. doi: 10.3390/v13061171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ponticelli D, Madotto F, Conti S, et al. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Internal and Emergency Medicine. 2021 doi: 10.1007/s11739-021-02857-y. doi: 10.1007/s11739-021-02857-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Balasco N, d’Alessandro V, Ferrara P, Smaldone G, Vitagliano L. Analysis of the time evolution of COVID-19 lethality during the first epidemic wave in Italy. Acta Biomedica. 2021;92(2):e2021171. doi: 10.23750/abm.v92i2.11149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Balasco N, d’Alessandro V, Smaldone G, Vitagliano L. Analysis of the time evolution of SARS-CoV-2 lethality rate in Italy: Evidence of an unaltered virus potency. medRxiv. 2020 doi: https://doi.org/10.1101/2020.06.12.20129387 . [Google Scholar]
  10. Dipartimento della Protezione Civile. COVID-19 Italia – Monitoraggio della situazione. Available online: www.opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1. (Last accessed on July 10, 2021) [Google Scholar]
  11. MATLAB R2014b, September 2014, MathWorks, Inc., Natick, Massachusetts, USA [Google Scholar]
  12. R Foundation for Statistical Computing. The R Foundation: Vienna, Austria. Available online: www.R-project.org . [Google Scholar]
  13. Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388:e19–23. doi: 10.1016/S0140-6736(16)30388-9. [DOI] [PubMed] [Google Scholar]
  14. Palmieri L, Palmer K, Lo Noce C, et al. Differences in the clinical characteristics of COVID-19 patients who died in hospital during different phases of the pandemic: national data from Italy. Aging Clinical and Experimental Research. 2021;33:193–199. doi: 10.1007/s40520-020-01764-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Istituto Superiore di Sanità. Characteristics of SARS-CoV-2 patients dying in Italy. Nov 18, 2020 Available online: https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_18_november_2020.pdf. (Last accessed on July 4, 2021) [Google Scholar]
  16. Cereda D, Tirani M, Rovida F, et al. The early phase of the COVID-19 outbreak in Lombardy, Italy. arXiv. 2003.09320 [q-bio.PE] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Appendix Supplementary files


Articles from Acta Bio Medica : Atenei Parmensis are provided here courtesy of Mattioli 1885

RESOURCES